Long-Term Prognostic Role of the Diagnostic Criteria for Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia

详细信息    查看全文

• 作者：Noriko Kikuchi ; MD ; Dai Yumino ; MD ; Tsuyoshi Shiga ; MD ; ^{mshiga@hij.twmu.ac.jp" class="auth_mail" title="E-mail the corresponding author} ; Atsushi Suzuki ; MD ; Nobuhisa Hagiwara ; MD
• 关键词：arrhythmia ; arrhythmogenic right ventricular cardiomyopathy/dysplasia ; diagnosis ; heart failure ; prognosis ; risk stratification
• 刊名：JACC: Clinical Electrophysiology
• 出版年：2016
• 出版时间：February 2016
• 年：2016
• 卷：2
• 期：1
• 页码：107-115
• 全文大小：650 K

文摘

The aim of this study was to evaluate the long-term prognostic role of the 2010 task force criteria (TFC)–based scoring in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia (ARVC/D).

Background

Categories of the 2010 TFC include the risk factors for cardiovascular mortality and sudden cardiac death in patients with ARVC/D.

Methods

Ninety patients with ARVC/D who met the definitive diagnosis of the 2010 TFC were retrospectively studied. ARVC/D risk score was calculated as the sum of major (2 points) and minor (1 point) criteria in all 6 subdivided categories of the TFC and was divided into tertile groups of scores; group A (4 to 6 points), group B (7 to 9 points), and group C (10 to 12 points). The primary endpoints were major adverse cardiovascular events: cardiovascular death, heart failure hospitalization, and sustained ventricular tachycardia or ventricular fibrillation.

Results

During the follow-up period of 10.2 ± 7.1 years, 19 patients died because of cardiovascular causes, 28 patients were admitted because of worsened heart failure, and 47 patients experienced sustained ventricular tachycardia or ventricular fibrillation. Patients in groups B and C were at increased risk for major adverse cardiovascular events compared with those in group A (hazard ratio [HR]: 4.80; 95% confidence interval [CI]: 1.87 to 12.33; p = 0.001; and HR: 6.15; 95% CI: 2.20 to 17.21; p = 0.001, respectively). Patients in groups B and C were at increased risk for sustained ventricular tachycardia or ventricular fibrillation compared with those in group A (HR: 6.64; 95% CI: 2.00 to 22.03; p = 0.002; and HR: 9.18; 95% CI: 2.60 to 32.40; p = 0.001, respectively).

Conclusions

Our study suggests that risk scoring based on the 2010 TFC is useful to predict major adverse cardiovascular events in patients with ARVC/D.